Key Facts
Chief Executive Officer:
 Lamberto Andreotti
Headquarters:
 New York City
Business:
 Biopharmaceuticals
Web Address:
 www.bms.com
NYSE Listing:
 BMY
Net Sales:
 $18.8 billion in 2009
R&D Investment:
 $3.6 billion in 2009
Largest-selling Products:
in 2009:
 PLAVIX®, $6.1 billion
ABILIFY®, $2.6 billion
REYATAZ®, $1.4 billion
AVAPRO®/AVALIDE®, $1.3 billion
SUSTIVA® franchise, $1.3 billion
Selected Key Products:
 ABILIFY® (aripiprazole)
ATRIPLA® (efavirenz / emtricitabine / tenofovir disoproxil fumarate)
AVAPRO® (irbesartan)
BARACLUDE® (entecavir)
ERBITUX® (cetuximab)
IXEMPRA™ (ixabepilone)
ORENCIA® (abatacept)
ONGLYZA™ (saxagliptin)
PLAVIX® (clopidogrel bisulfate)
REYATAZ® (atazanavir sulfate)
SPRYCEL® (dasatinib)
SUSTIVA® (efavirenz)
Principal Locations:
 Worldwide Facilities

Please click on the product links to see the full prescribing information including Boxed WARNINGS for ABILIFY®, ATRIPLA®, BARACLUDE®, ERBITUX®, and Boxed WARNINGS for AVAPRO® and AVALIDE® regarding use in pregnancy. As soon as pregnancy is detected, discontinue use of AVAPRO® or AVALIDE®.